Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus

Immunology

Volumn 145, Issue 4, 2015, Pages 476-484

  Guo, Xiaojuan ^a   Deng, Yao ^a   Chen, Hong ^a   Lan, Jiaming ^a,b   Wang, Wen ^a   Zou, Xiaohui ^a   Hung, Tao ^a   Lu, Zhuozhuang ^a   Tan, Wenjie ^a  

^a BEIJING HOSPITAL   (China)

^b HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Adenoviral vector; Immunity; Middle East respiratory syndrome coronavirus; Spike protein; Vaccine

Indexed keywords

IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; RECOMBINANT ADENOVIRAL TYPE 41 VACCINE; RECOMBINANT ADENOVIRAL TYPE 5 VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VACCINE; CORONAVIRUS SPIKE GLYCOPROTEIN; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIGEN SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN ADENOVIRUS 41; HUMAN ADENOVIRUS 5; HUMAN ADENOVIRUS C; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IN VIVO STUDY; LUNG; LYMPHOCYTE; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; SERUM; SINGLE DRUG DOSE; SPLEEN; T LYMPHOCYTE; TH1 CELL; VACCINATION; ADENOVIRIDAE; ANIMAL; CORONAVIRUS INFECTIONS; GENETICS; IMMUNOLOGY; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; TRANSMISSION;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BASE SEQUENCE; CORONAVIRUS INFECTIONS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, MUCOSAL; IMMUNIZATION; IMMUNOGLOBULIN G; MICE; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MOLECULAR SEQUENCE DATA; SPIKE GLYCOPROTEIN, CORONAVIRUS; T-LYMPHOCYTES; VIRAL VACCINES;

EID: 84936205833     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12462     Document Type: Article

References (39)

1. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012; 367:1814-20.
2. Bermingham A, Chand MA, Brown CS et al. Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East. Euro Surveill 2012; 17:20290.
3. de Groot RJ, Baker SC, Baric RS et al. Middle East Respiratory Syndrome Coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J Virol 2013; 87:7790-2.
4. WHO. Middle East respiratory syndrome coronavirus (MERS-CoV), update. 26 December 2014.
5. van Boheemen S, de Graaf M, Lauber C et al. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio 2012; 3:e00473-12.
6. Raj VS, Mou H, Smits SL et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013; 495:251-4.
7. Du LY, Zhou YS, Liu SW, Zheng BJ, Jiang S. The spike protein of SARS-CoV-a target for vaccine and therapeutic development. Nat Rev Microbiol 2009; 7:226-36.
8. Song F, Fux R, Provacia LB et al. Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies. J Virol 2013; 87:11950-4.
9. Gierer S, Bertram S, Kaup F et al. The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated byTMPRSS2, and is targeted by neutralizing antibodies. J Virol 2013; 87:5502-11.
10. Shiver JW, Emini EA. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med 2004; 55:355-72.
11. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000; 408:605-9.
12. Sullivan NJ, Geisbert TW, Geisbert JB et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 2003; 424:681-4.
13. Arnberg N. Adenovirus receptors: implications for targeting of viral vectors. Trends Pharmacol Sci 2012; 33:442-8.
14. Lemiale F, Kong WP, Akyurek LM, Ling X, Huang Y, Chakrabarti BK, Eckhaus M, Nabel GJ. Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J Virol 2003; 77:10078-87.
15. Lu ZZ, Zou XH, Dong LX, Qu JG, Song JD, Wang M, Guo L, Hung T. Novel recombinant adenovirus type 41 vector and its biological properties. J Gene Med 2009; 11:128-38.
16. Catanzaro AT, Koup RA, Roederer M et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 2006; 194:1638-49.
17. Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006; 6:148-58.
18. Ko SY, Cheng C, Kong WP et al. Enhanced induction of intestinal cellular immunity by oral priming with enteric adenovirus 41 vectors. J Virol 2009; 83:748-56.
19. + T lymphocytes. J Virol 2010; 84:5986-96.
20. Lu ZZ, Zou XH, Lastinger K, Williams A, Qu JG, Estes DM. Enhanced growth of recombinant human Adenovirus type 41 (HAdV-41) carrying ADP gene. Virus Res 2013; 176:61-8.
21. Lu G, Hu Y, Wang Q et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 2013; 500:227-31.
22. Zhao G, Ma C, Li D, Li L, Vincent KM, Poon WL, Yu F et al. A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV. Virol J 2013; 10:266-73.
23. Gao J, Lu G, Qi J et al. Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus. J Virol 2013; 87:13134-40.
24. Chuai X, Wang W, Chen H, Deng Y, Wen B, Tan W. Lentiviral backbone-based hepatitis B virus replicon-mediated transfer favours the establishment of persistent hepatitis B virus infection in mice after hydrodynamic injection. Antiviral Res 2014; 101:68-74.
25. Wang J, Tricoche N, Du L et al. The adjuvanticity of an O. volvulus-derived rOv-ASP-1 protein in mice using sequential vaccinations and in non-human primates. PLoS ONE 2012; 7:e37019.
26. Mizuguchi H, Kay MA, Hayakawa T. Approaches for generating recombinant adenovirus vectors. Adv Drug Deliv Rev 2001; 52:165-76.
27. Danthinne X, Imperiale MJ. Production of first generation adenovirus vectors: a review. Gene Ther 2000; 7:1707-14.
28. Raviprakash K, Wang D, Ewing D et al. A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus. J Virol 2008; 82:6927-34.
29. Lemiale F, Haddada H, Nabel GJ, Brough DE, King CR, Gall JG.Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41. Vaccine 2007; 25:2074-84.
30. Wang M, Chen DL, Song JD, Qu JG, Lu ZZ, Zhao WM, Hong T. The genetic stability of recombinant adenovirus expressing human rotavirus VP6 gene which used Ad41 as vector. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2012; 26:422-4.
31. Zhou Q, Hidajat R, Peng B et al. Comparative evaluation of oral and intranasal priming with replication-competent adenovirus 5 host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIV-(mac251). Vaccine 2007; 25:8021-35.
32. Channappanavar R, Zhao J, Perlman S. T cell-mediated immune response to respiratory coronaviruses. Immunol Res 2014; 59:118-28.
33. Channappanavar R, Fett C, Zhao J, Meyerholz DK, Perlman S. Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection. J Virol 2014; 88:11034-44.
34. Kim E, Okada K, Beeler JA, Crim RL, Piedra PA, Gilbert BE, Gambotto A. Development of an adenovirus-based respiratory syncytial virus vaccine: preclinical evaluation of efficacy, immunogenicity, and enhanced disease in a cotton rat model. J Virol 2014; 88:5100-8.
35. Zeng M, Xu Q, Elias M, Pichichero ME, Simpson LL, Smith LA. Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine. Vaccine 2007; 25:7540-8.
36. Ma C, Li Y, Wang L et al. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: implication for designing novel mucosal MERS vaccines. Vaccine 2014; 32:2100-8.
37. Seregin SS, Amalfitano A. Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors. Expert Opin Biol Ther 2009; 9:1521-31.
38. Madani TA, Azhar EI, Hashem AM. Evidence for camel-to-human transmission of MERS coronavirus. N Engl J Med 2014; 371:1360.
39. Kim E, Okada K, Kenniston T et al. Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice. Vaccine 2014; 32:5975-82.